A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Clinical trial NCT06925321 · RECRUITING

Trial details

NCT number: NCT06925321
Sponsor: Basilea Pharmaceutica
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Invasive Mold Infections

Start date: 2025-08-26
Primary completion: 2028-02-01
Enrollment: 234

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.